A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation

Transplantation

Volumn 87, Issue 3, 2009, Pages 408-414

  Walker, Jennifer K ^a   Alloway, Rita R ^a,b   Roy Chaudhury, Prabir ^b   Mogilishetty, Gautham ^b   Cardi, Michael A ^c   Weimert, Nicole A ^b   Rike, Adele H ^a   First, M Roy ^d   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHRIST HOSPITAL   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Calcineurin inhibitor minimization; Corticosteroid free; HLA identical; Kidney transplantation

Indexed keywords

ATORVASTATIN; BASILIXIMAB; CORTICOSTEROID; CREATININE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMOLYTIC ANEMIA; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION TEST; LIVING DONOR; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; BLOOD; BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME;

ADRENAL CORTEX HORMONES; BLOOD PRESSURE; CHOLESTEROL; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVING DONORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 61849156866     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318194515c     Document Type: Article

References (32)

1. Takiff H, Cook DJ, Himaya NS, et al. Dominant effect of histocom-patibility on ten-year kidney transplant survival. Transplantation 1988; 45: 410.
2. Terasaki PI, Cho Y, Takemoto S, et al. Twenty-year follow-up on the effectof HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc 1996; 28: 1144.
3. Terasaki PI. The HLA-matching effect in different cohorts of kidney transplant recipients. Clin Transpl 2000; 497.
4. United Network for Organ Sharing [database on the internet]. Richmond, VA, Organ Procurement and Transplantation Network data 2006 [cited March 23, 2007]. Available at: http://unos.org/.
5. Shimmura H, Tanabe K, Ishida H, et al. Long-term results of living kidney transplantation from HLA-identical sibling donors under calcineurin inhibitor immunosuppression. Int J Urol 2006; 13: 502.
6. Moon JI, Kim YS, Chung SY, et al. Long-term results of kidney transplantation between HLA-identical siblings. Surg Today 2001; 31: 123.
7. de Mattos AM, Bennett WM, Barry JM, et al. HLA-identical sibling renal transplantation - A 21-yr single-center experience. Clin Transplant 1999; 13: 158.
8. Peddi VR, Weiskittel P, Alexander JW, et al. HLA-identical renal transplant recipients: Immunosuppression, long-term complications, and survival. Transplant Proc 2001; 33: 3411.
9. Keitel E, Santos AF, Alves MA, et al. Immunosuppression protocols for HLA identical renal transplant recipients. Transplant Proc 2003; 35: 1074.
10. Ascher NL, Simmons RL, Noreen H, et al. 100 HLA-identical sibling transplants. Ann Surg 1979; 189: 209.
11. SumraniN, Delaney V, Ding Z,Butt K,et al. HLA-identical renal transplants: Impact of cyclosporine onintermediate-term survival and renal function. Am J Kidney Dis 1990; 16: 417.
12. Sumrani N, Delaney V, Ding Z, et al. Is cyclosporine indicated in HLA-identical renal transplant recipients? Transplant Proc 1991; 23: 1239.
13. Albrechtsen D, Flatmark A, Leivestad T, et al. Efficacy of cyclosporine in renal transplantation from HLA haploidentical living donors: No benefit oftransfusionoradditional azathioprine. Transplant Proc 1990; 22: 214.
14. Schweizer RT, Roper L, HullD,et al. Low-dose triple immunosuppres-sion for HLA identical sibling kidney transplants. Transplant Proc 1992; 24: 2609.
15. Van Buren D, MacDonell R, Johnson HK, et al. Cyclosporine improves results in HLA-identical sibling renal transplants. Transplant Proc 1994; 26: 2514.
16. Gill IS, Hodge EE, Novick AC, et al. Azathioprine vs cyclosporine in recipients of HLA-identical renal allografts. Cleve Clin J Med 1994; 61: 206.
17. Kirk AD, Mannon RD, Swanson SJ, et al. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2.
18. Yang H. Maintenance immunosuppression regimens: Conversion, minimization, withdrawal, and avoidance. Am J Kidney Dis 2006; 47: S37.
19. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740.
20. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immuno-suppression in renal transplant recipients. Transplantation 1988; 45: 323.
21. MacDonald AS, Belitsky P, Bitter-Suermann H, et al. Cyclosporine as primary therapy for a matched living related donor kidney graft recipients. Transplant Proc 1989; 21: 1667.
22. Kramer BK, Zulke C, Kammerl MC, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing cal-cineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982.
23. Alexander JW, Goodman HR, Cardi M, et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006; 19: 295.
24. Jaber JJ, Feustel PJ, Elbahloul O, et al. Early steroid withdrawal therapy in renal transplant recipients: A steroid-free sirolimus and cellcept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007; 21: 101.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143.
26. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289: 2560.
27. Keunecke C, Rothenpieler U, Zanker B, et al. Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000; 32(suppl 1A): 6S.
28. Govil A, Golconda MS, Olyaei AJ, et al. Calcineurin inhibitor with-drawl in HLA-identical sibling kidney transplant recipients: A 10-year single center experience. Transplantation 2006; 82(1 suppl 2): 285.
29. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369.
30. The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction ofacute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194.
31. The Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclo-sporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
32. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531.